Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hongcheng Wu
Institution:
Ningbo Medical Center Lihuili Hospital
Observed institution:
Ningbo Medical Center Lihuili Hospital
ORCID:
0000-0002-5736-5743
Observed ORCID:
0000-0002-5736-5743
OpenAlex ID:
A5055996707
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
2025
·
Zhiwei Chen
, Fang Yang
, et al.
·
The Lancet
·
63
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
2026
·
Shun Lu
, Jie Wang
, et al.
·
The Lancet
·
46
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
2026
·
Shun Lu
, Baogang Liu
, et al.
·
The Lancet
·
27
Plain language summary: comparing ivonescimab with pembrolizumab in people with PD-L1–positive non-small cell lung cancer in the HARMONi–2 study
2025
·
Lei Wang
, Wenxiu Yao
, et al.
·
Future Oncology
·
1
PDF
Plain language summary: comparing ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in people with advanced squamous non-small cell lung cancer in the HARMONi-6 study
2026
·
Zhiwei Chen
, Fang Yang
, et al.
·
Future Oncology
Show more works
View as search
Works count:
5
Citation count:
137
H-index:
3
I10-index:
3
Year
Topic
Type